Does empagliflozin reduce BP and HbA1c in patients with type 2 diabetes and hypertension?
Empagliflozin provides clinically meaningful reductions in blood pressure and HbA1c in patients with comorbid type 2 diabetes and hypertension.
Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Tikkanen et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: